BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30693893)

  • 21. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
    Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of EGFR Mutations and Clinico-Pathological Characteristics of Chilean Lung Cancer Patients.
    Gejman R; González S; Muñoz-Medel M; Nervi B; Sánchez C; Ibáñez C; Peña J; Madrid J; Briones J; Pérez P; Garrido M; Galindo H
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):1-4. PubMed ID: 30677862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
    Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
    BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validity of Natural Language Processing for Ascertainment of
    Goulart BHL; Silgard ET; Baik CS; Bansal A; Sun Q; Durbin EB; Hands I; Shah D; Arnold SM; Ramsey SD; Kavuluru R; Schwartz SM
    JCO Clin Cancer Inform; 2019 May; 3():1-15. PubMed ID: 31058542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma.
    Arfaoui Toumi A; Blel A; Aloui R; Zaibi H; Ksentinini M; Boudaya MS; Znaidi N; Zidi Y; Aouina H; Rammeh Rommani S
    Curr Res Transl Med; 2018 Sep; 66(3):65-70. PubMed ID: 29540329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study.
    Esteban E; Majem M; Martinez Aguillo M; Martinez Banaclocha N; Dómine M; Gómez Aldaravi L; Juan O; Cajal R; Gonzalez Arenas MC; Provencio M
    Cancer Epidemiol; 2015 Jun; 39(3):291-7. PubMed ID: 25766256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
    Zhou J; Song XB; He H; Zhou Y; Lu XJ; Ying BW
    Asian Pac J Cancer Prev; 2016; 17(3):965-71. PubMed ID: 27039821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
    Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of EGFR mutations in lung adenocarcinoma patients - A study from tertiary cancer center of South India.
    Nayanar SK; Mohan A; Shenoy P; Saravanan M; Gopinath V; Deepak Roshan VG
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S712-S718. PubMed ID: 38384044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of
    Loubière S; Drezet A; Beau-Faller M; Moro-Sibilot D; Friard S; Wislez M; Blons H; Daniel C; Westeel V; Madroszyk A; Léna H; Merle P; Mazières J; Zalcman G; Lacave R; Antoine M; Morin F; Missy P; Barlesi F; Auquier P; Cadranel J;
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545318
    [No Abstract]   [Full Text] [Related]  

  • 37. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
    Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
    Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis.
    Itchins M; Hayes SA; Gill AJ; Cooper W; O'Connell R; Howell VM; Clarke SJ; Pavlakis N
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e275-e282. PubMed ID: 29675948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
    Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.
    Van Der Steen N; Mentens Y; Ramael M; Leon LG; Germonpré P; Ferri J; Gandara DR; Giovannetti E; Peters GJ; Pauwels P; Rolfo C
    Clin Lung Cancer; 2018 Jan; 19(1):35-41. PubMed ID: 28757336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.